Pancreatic Cancer
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival A once-“undruggable” pancreatic cancer target has finally been cracked, and the new treatment nearly doubled survival in a landmark trial. - Date: - June 4, 2026 - Source: - The Conversation - Summary: -
Pancreatic cancer: New drug extends lives but isn't a cure
Pancreatic cancer: New drug extends lives but isn't a cure June 8, 2026Pancreatic cancer is notoriously difficult to treat — and in many cases leads to death just months after diagnosis. So it is no surprise that this headline created a stir: In a recent study, a new drug, daraxonrasib, was able to double the survival time of patients with pancreatic cancer. Compared with patients who underwent chemotherapy, those treated with daraxonrasib not only lived longer, but also reported a better...
One fat helped pancreatic cancer grow while another cut disease in half
One fat helped pancreatic cancer grow while another cut disease in half - Date: - June 2, 2026 - Source: - Yale School of Medicine - Summary: - A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how much. Researchers found that oleic acid—the main fat in olive oil and several other common foods—sped up tumor growth in mice predisposed to pancreatic cancer, while omega-3-rich fats from fish oil dramatically slowed disease...
After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
Every single patient with advanced pancreatic cancer who walked into Dr. Zev Wainberg’s office told him they would rather take an experimental medication than endure another round of chemotherapy. Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib. All the study participants previously had chemotherapy that was starting to fail.
Matched pancreatic cancer liver metastatic model system reveals cancer cell-dependent organotropism and site-specific tumor microenvironment reflective of human disease
Pancreatic ductal adenocarcinoma (PDAC) is a deadly, highly metastatic disease, driven by an interplay between cancer cells and the metastatic site-specific microenvironment. However, pre-clinical models that robustly capture these interactions within the context of matched primary and metastatic tumors are limited. Here, we present a novel transplant model system for matched pancreas and liver tumors to study PDAC metastatic progression.
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
A new drug for advanced pancreatic cancer is being hailed as a major breakthrough after trial results showed that it almost doubles survival time in patients previously treated with chemotherapy. Phase 3 trial results for daraxonrasib, a once daily oral treatment, have been described as a potential “revolution” in treating pancreatic cancer, which has the lowest survival of all common cancers, with five year survival less than 7%.In the RASolute 302 trial of 500 patients with metastatic...
Experimental pill promises new hope for deadly pancreatic cancer
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.(Image credit: Min Yu/AP)
'Transformative' pancreatic cancer drug doubles survival time
A daily pill doubles the survival time of people with pancreatic cancer, one of the most aggressive and difficult-to-treat forms of the condition, even after they have stopped responding to chemotherapy. What’s more, the convenient pill has fewer side effects than standard chemotherapy. “It’s a transformative treatment,” says Pilar Acedo at University College London, who wasn’t involved in the research.
Pancreatic cancer: Dr. Pudlarz praises 'new generation targeted therapy' that inhibits gene mutation
Oliver Farry is pleased to welcome Dr. Thomas Pudlarz, Medical Oncologist and Head of the pancreatic care pathway within the 'Interception' program at the Gustave-Roussy Institute. For decades, pancreatic cancer has remained one of oncology's most formidable challenges. Despite major advances in immunotherapy and precision medicine, treatment for pancreatic cancer remains elusive.
Detection of Pancreatic Cancer Using a Methylation-Specific PCR-Based Multi-Cancer Early Detection Test
Context: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy often diagnosed at advanced stages due to the lack of early clinical symptoms. DNA methylation alterations arise early in PDAC tumorigenesis and may serve as promising biomarkers for blood-based cancer detection. Objective: To evaluate the performance of EPISEEK, a laboratory-developed blood-based multi-cancer early detection (MCED) assay, for detecting PDAC across disease stages.